Healthcare stocks were mixed pre-bell Tuesday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.5% and the iShares Biotechnology ETF (IBB) 0.3% lower.
Natera (NTRA) has received a Category 1 recommendation from the National Comprehensive Cancer Network for Signatera-guided adjuvant atezolizumab treatment in patients with muscle-invasive bladder cancer, the company said. Natera shares were down more than1% premarket.